
    
      The scope of this open label clinical trial is to evaluate and confirm the performance of
      DermoRelizema ecofoam in the improvement of the dermatitis severity, by alleviating the
      symptomatology. The product will be applied for 42 days of treatment, 2 times per day into
      the face.

      The dermatologist will perform 3 clinical follow up visits to assess the efficacy and safety
      of the product
    
  